This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Rocket Stocks Worth Buying This Week

Alexion Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

There's no two ways about it -- it's been a phenomenal year for shares of Alexion Pharmaceuticals (ALXN - Get Report). Shares of the $20 billion pharmaceutical firm have rallied 50% since the first trading day of January, besting the broad market's performance by a wide margin.

Alexion emerged from obscurity on the heels of its Soliris drug, a treatment for rare blood disorders. By focusing on niche treatments of rare diseases, Alexion gets the big benefits of orphan drug status, and it doesn't have to compete with big pharma rivals.

>>10 Stocks of Top-Performing Mutual Funds in 2012

While Soliris is Alexion's sole drug, the firm has been working to gain its FDA approval for other autoimmune diseases. The result is more sales without more development costs associated with trying to bring other drugs to market. It's a perfect strategy for an orphan drug, which gets longer patent protection, and Soliris has already proven useful for other indications.

That performance has helped the firm build a large cash backstop (more than $800 million at last count, offset by some added debt from its Enobia acquisition) that should help to fuel its future R&D costs. Let me be clear, though: ALXN isn't a cheap stock right now; it's actually quite overpriced. But momentum continues to be rock-solid in this stock, and buyers aren't scarce.

That's why ALXN gets Rocket Stock status this week.
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ALXN $139.28 -2.28%
IR $65.54 0.32%
PPL $37.64 0.99%
TSCO $94.66 -0.33%
WFM $29.08 -2.38%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs